Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

2007 • 4,669 citations

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

2007 • 3,560 citations

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

2008 • 2,937 citations

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

2003 • 2,458 citations

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

2011 • 1,767 citations

Phase 3 trial of everolimus for metastatic renal cell carcinoma

2010 • 1,125 citations

Analysis of survival by tumor response.

1983 • 1,021 citations

Analysis of survival by tumor response.

1986 • 1,018 citations

Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma

2004 • 778 citations

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

2008 • 587 citations

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

2011 • 570 citations

Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival

2009 • 454 citations

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

2007 • 430 citations

Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma

2013 • 386 citations

Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma

2009 • 325 citations

Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors

2011 • 182 citations

Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma

2011 • 117 citations

Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).

2006 • 96 citations

Development and Validation of a Scale to Measure Disease-Related Symptoms of Kidney Cancer

2007 • 91 citations

Temsirolimus vs Sorafenib As Second Line Therapy in Metastatic Renal Cell Carcinoma: Results from the Intorsect Trial

2012 • 64 citations

General population norms for the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)

2012 • 28 citations

Progression Free Survival

2009 • 17 citations

Interpreting Overall Survival (OS) Results When Progression Free Survival (PFS) Benefits Exists in Today's Oncology Landscape - Metastatic Renal Cell Carcinoma (Mrcc) Case Study

2012 • 1 citations